Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma.

ABSTRACT:

Background

Although some clinical trials have demonstrated the benefits of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC), its optimal candidate has not been clarified. This study aimed to detect predictive prognostic factors for resectable PDAC patients who underwent upfront surgery and identify patient cohorts with long-term survival without neoadjuvant therapy.

Patients and methods

A total of 232 patients with resectable PDAC who underwent upfront surgery between January 2008 and December 2019 were evaluated.

Results

The median overall survival (OS) time and 5-year OS rate of resectable PDAC with upfront surgery was 31.5 months and 33.3%, respectively. Multivariate analyses identified tumor diameter in computed tomography (CT) ≤ 19 mm [h

SUBMITTER: Konishi T 

PROVIDER: S-EPMC11413041 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature